HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...

Use of nucleoside reverse transcriptase inhibitors (NRTIs), but not other medications for HIV, was associated with a significantly reduced risk for Alzheimer’s disease (AD) in an analysis of two ...

Rome Therapeutics Inc. has synthesized 4’-halomethyl-cytidine phosphoramidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors ...

Rome Therapeutics Inc. has synthesized cyclopentene-oxymethylene phosphonamidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase ...

DOR/ISL was noninferior to BIC/FTC/TAF based on the percentage of patients with HIV-1 RNA levels 50 copies/mL at week 48. Topline data were announced from a phase 3 trial evaluating ...

Scientists have identified promising real-world links between common HIV drugs and a reduced incidence of Alzheimer's disease. Alzheimer's disease (AD) currently afflicts nearly seven million people ...

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.